Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients

Metastatic Colon Cancer, Version 3.2013

(2017) Al B. Benson et al.   Journal of the National Comprehensive Cancer Network

Pharmacokinetic evaluation of capecitabine in breast cancer

(2013) Gennaro Daniele et al.   Expert Opinion on Drug Metabolism & Toxicology

Dermatologic Presentations of Orthopedic Pathologies

(2012) Daniel Marchalik et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer

(2012) Siddharth Chachad et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study

(2012) Olivier Capitain et al.   Clinical Colorectal Cancer

Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity

(2012) Christian Woloch et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

(2012) Christophe Tournigand et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6

(2012) R. R. Kaldate et al.   ONCOLOGIST

Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

(2012) Michèle Boisdron-Celle   PHARMACOGENOMICS

Target Concentration Intervention in Oncology

(2012) Mohamed Saleem et al.   THERAPEUTIC DRUG MONITORING

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

(2011) Maurice C. van Staveren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Adjuvant treatment of colon cancer: what is next?

(2011) Katherine Van Loon et al.   CURRENT OPINION IN ONCOLOGY

Time-Dependent Pharmacokinetics of 5-Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer

(2011) Toni Ibrahim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

(2011) C. Hiemke et al.   PHARMACOPSYCHIATRY

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes

(2009) M. Wasif Saif et al.   JNCI-Journal of the National Cancer Institute

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

(2008) Erick Gamelin et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene

(2008) A. B. P. van Kuilenburg et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation

(2007) Imke H. Bartelink et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION